A new peer-reviewed study concluded that the mortality rate in people who used ivermectin regularly was 92 percent lower than in non-users and 84 percent lower than in irregular users.
Among the authors are Flávio Cadegiani, a board-certified endocrinologist, and Pierre Kory, an outspoken pulmonary and critical care medicine specialist, as well as president and chief medical officer of the Front Line Critical Care Alliance.
The study, published on Aug. 31 in the Cuerus Journal of Medical Science, was conducted via a prospective observational study of a “strictly controlled population” of 88,012 subjects in the Brazilian city of Itajaí.
The individuals that took ivermectin as a preventive medicine prior to COVID infection saw remarkable reductions in hospitalization as well as death, according to the publication….